Recordati Acquires Rights to Enjaymo from Sanofi for $825 Million
By Daniella Parra Recordati said it will acquire the global rights to Enjaymo, used to treat a rare blood disorder, from Sanofi. Enjaymo has been approved by the FDA, European Commission, and Japan’s Ministry of Health, the company said. Recordati...